Keyword: Oxford University
In its latest development deal, the outbreak readiness group CEPI has awarded J&J and Oxford University $14.6 million for work on a MERS vaccine.
The partnership aims to make the production of vaccines that use adenovirus as vectors more cost-effective and contamination-free.
Here's some other vaccine news of note for the week.
The £20 million series A backed by GV will help Vaccitech develop an MVA-vectored universal flu vaccine currently in phase 2.
Researchers in England are kicking off the world's first large human trial of a "universal" influenza shot.
With a universal flu vaccine candidate serving as its lead product, University of Oxford spinoff Vaccitech launched this week with £10 million and plans to get busy.